Abstract
Endothelial dysfunction and accelerated atherosclerosis lead to increased cardiovascular morbidity and mortality in patients with rheumatoid arthritis and other inflammatory rheumatic diseases. Sustained inflammation is a major risk factor for cardiovascular disease. Apart from traditional vasculoprotective agents, biologic agents may also exert favorable effects on the vasculature. Indeed, agents that inhibit tumor necrosis factor (TNF) seem to transiently improve endothelial function. Data regarding the effects of biologic agents on atherosclerosis and arterial stiffness are inconsistent. The effects of the various TNF blockers on dyslipidemia might differ: long-term infliximab therapy could be pro-atherogenic, whereas some studies suggest that etanercept and adalimumab may exert beneficial effects on the lipid profile. TNF blockers have been shown to decrease the incidence of cardiovascular events in patients with rheumatoid arthritis. Preliminary data suggest that rituximab also improves endothelial function and dyslipidemia. Further studies are needed to determine the net effects of biologic agents on the vasculature.
Key Points
-
Accelerated atherosclerosis and increased cardiovascular morbidity and mortality have been associated with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA)
-
The suppression of systemic inflammation and clinical activity of RA, AS or PsA can attenuate atherosclerosis and decrease the risk of cardiovascular disease
-
Biologic agents, including TNF inhibitors and rituximab, might transiently improve endothelial function and could also decrease carotid atherosclerosis and arterial stiffness
-
Biologic agents might have beneficial metabolic effects as they may influence dyslipidemia, lipokine production and insulin resistance
-
Vascular and metabolic effects of biologic agents could translate into clinical importance, as they might improve cardiovascular outcome
-
Data emerging from mostly small, short-term studies are conflicting; therefore, larger follow-up studies are needed to confirm the vascular effects of biologic agents in RA and other types of arthritis
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kerekes, G. et al. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J. Rheumatol. 35, 398–406 (2008).
Giles, J. T., Post, W., Blumenthal, R. S. & Bathon, J. M. Therapy insight: managing cardiovascular risk in patients with rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 2, 320–329 (2006).
Shoenfeld, Y. et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112, 3337–3347 (2005).
Szekanecz, Z. et al. Accelerated atherosclerosis in rheumatoid arthritis. Ann. NY Acad. Sci. 1108, 349–358 (2007).
Nurmohamed, M. T. Cardiovascular risk in rheumatoid arthritis. Autoimmun. Rev. 8, 663–667 (2009).
Kaplan, M. J. Cardiovascular disease in rheumatoid arthritis. Curr. Opin. Rheumatol. 18, 289–297 (2006).
Szekanecz, Z. & Koch, A. E. Vascular involvement in rheumatic diseases: 'vascular rheumatology'. Arthritis Res. Ther. 10, 224 (2008).
Ross, R. Atherosclerosis—an inflammatory disease. N. Engl. J. Med. 340, 115–126 (1999).
Klareskog, L., Padyukov, L., Lorentzen, J. & Alfredsson, L. Mechanisms of disease: genetic susceptibility and environmental triggers in the development of rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 2, 425–433 (2006).
Rosenvinge, A., Krogh-Madsen, R., Baslund, B. & Pedersen, B. K. Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFα therapy. Scand. J. Rheumatol. 36, 91–96 (2007).
Kiortsis, D. N., Mavridis, A. K., Vasakos, S., Nikas, S. N. & Drosos, A. A. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann. Rheum. Dis. 64, 765–766 (2005).
Gonzalez-Gay, M. A. et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 24, 83–86 (2006).
Solomon, D. H. et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107, 1303–1307 (2003).
Maradit-Kremers, H. et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 52, 402–411 (2005).
Montecucco, F. & Mach, F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford) 48, 11–22 (2009).
Ohsuzu, F. The roles of cytokines, inflammation and immunity in vascular diseases. J. Atheroscler. Thromb. 11, 313–321 (2004).
Gonzalez-Gay, M. A. et al. Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 24, 373–379 (2006).
Libby, P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am. J. Med. 121 (10 Suppl. 1), S21–S31 (2008).
McKellar, G. E., McCarey, D. W., Sattar, N. & McInnes, I. B. Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat. Rev. Cardiol. 6, 410–417 (2009).
Dixon, W. G. & Symmons, D. P. What effects might anti-TNFα treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFα in cardiovascular pathophysiology. Ann. Rheum. Dis. 66, 1132–1136 (2007).
Szekanecz, Z., Shah, M. R., Pearce, W. H. & Koch, A. E. Interleukin-8 and tumor necrosis factor-α are involved in human aortic endothelial cell migration: the possible role of these cytokines in human aortic aneurysmal blood vessel growth. Pathobiology 62, 134–139 (1994).
Gonzalez-Gay, M. A. et al. Anti-TNF-α therapy modulates resistin in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 26, 311–316 (2008).
Migita, K. et al. The serum levels of resistin in rheumatoid arthritis patients. Clin. Exp. Rheumatol. 24, 698–701 (2006).
Toussirot, E., Streit, G. & Wendling, D. The contribution of adipose tissue and adipokines to inflammation in joint diseases. Curr. Med. Chem. 14, 1095–1100 (2007).
Senolt, L. et al. Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Ann. Rheum. Dis. 66, 458–463 (2007).
Komai, N., Morita, Y., Sakuta, T., Kuwabara, A. & Kashihara, N. Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis. Mod. Rheumatol. 17, 385–390 (2007).
Kapoor, S. Anti-inflammatory and anti-atherogenic effects of adiponectin in patients with rheumatoid arthritis following anti-TNF therapy. Scand. J. Rheumatol. 38, 158 (2009).
Otero, M. et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann. Rheum. Dis. 65, 1198–1201 (2006).
Pieringer, H., Schumacher, S., Stuby, U. & Biesenbach, G. Augmentation index and large-artery remodelling in patients with longstanding rheumatoid arthritis compared with healthy controls. Semin. Arthritis Rheum. doi:10.1016/j.semarthrit.2008.08.005.
Giles, J. T. et al. Coronary arterial calcification in rheumatoid arthritis: comparison with the Multi-Ethnic Study of Atherosclerosis. Arthritis Res. Ther. 11, R36 (2009).
Wållberg-Jonsson, S. K., Caidahl, K., Klintland, N., Nyberg, G. & Rantapää-Dahlqvist, S. Increased arterial stiffness and indication of endothelial dysfunction in long-standing rheumatoid arthritis. Scand. J. Rheumatol. 37, 1–5 (2008).
Soltész, P. et al. A comparative study of arterial stiffness, flow-mediated vasodilation of the bracial artery and the thickness of carotid artery intima-media in patients with systemic autoimmune diseases. Clin. Rheumatol. 28, 655–662 (2009).
Mäki-Petäjä, K. M. et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-α therapy. Circulation 114, 1185–1192 (2006).
Han, C. et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. J. Rheumatol. 33, 2167–2172 (2006).
Heeneman, S. & Daemen, M. J. Cardiovascular risks in spondyloarthritides. Curr. Opin. Rheumatol. 19, 358–362 (2007).
Pieringer, H. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford) 45, 1319 (2006).
van Eijk, I. C. et al. Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. Ann. Rheum. Dis. 68, 362–366 (2009).
Moyssakis, I. et al. Myocardial performance and aortic elasticity are impaired in patients with ankylosing spondylitis. Scand. J. Rheumatol. 18, 1–6 (2009).
Choe, J. Y. et al. No differences of carotid intima-media thickness between young patients with ankylosing spondylitis and healthy controls. Joint Bone Spine 75, 548–553 (2008).
Mathieu, S. et al. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology (Oxford) 47, 1203–1207 (2008).
Kimhi, O. et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin. Arthritis Rheum. 36, 203–209 (2007).
Späh, F. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential of an integrated treatment approach. Br. J. Dermatol. 159 (Suppl. 2), 10–17 (2008).
Channual, J., Wu, J. J. & Dann, F. J. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis. Dermatol. Ther. 22, 61–73 (2009).
Peters, M. J., Symmons, D. P. M., McCarey, D. W. & Nurmohamed, M. T. Cardiovascular risk management in patients with rheumatoid arthritis and other types of inflammatory arthritis: a EULAR task force. Arthritis Rheum. 58 (Suppl. 9), S421 (2008).
Gonzalez-Juanatey, C. et al. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor α blocker therapy. Arthritis Rheum. 59, 1821–1824 (2008).
Kerekes, G. et al. Effects of rituximab treatment on endothelial dysfunction and lipid profile in rheumatoid arthritis. Clin. Rheumatol. 28, 705–710 (2009).
Hürlimann, D. et al. Anti-tumor necrosis factor-α treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106, 2184–2187 (2002).
Bilsborough, W. et al. Anti-tumour necrosis factor-α therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis. Rheumatol. Int. 26, 1125–1131 (2006).
Gonzalez-Juanatey, C. et al. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor-α antibody. Arthritis Rheum. 51, 447–450 (2004).
Bosello, S. et al. TNF-α blockade induces a reversible but transient effect of endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. Clin. Rheumatol. 27, 833–839 (2008).
Gonzalez-Juanatey, C. et al. Short-term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab. Clin. Exp. Rheumatol. 24, 309–312 (2006).
Del Porto, F. et al. Response to anti-tumour necrosis factor α blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology (Oxford) 46, 1111–1115 (2007).
Wong, M. et al. Infliximab improves vascular stiffness in patients with rheumatoid arthritis. Ann. Rheum. Dis. 68, 1277–1284 (2008).
Van Doornum, S., McColl, G. & Wicks, I. P. Tumour necrosis factor antagonists improve the disease activity but not arterial stiffness in rheumatoid arthritis. Rheumatology (Oxford) 44, 1428–1432 (2005).
Vis, M. et al. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J. Rheumatol. 32, 252–255 (2005).
Seriolo, B. et al. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann. NY Acad. Sci. 1069, 414–419 (2006).
Tam, L. S., Tomlinson, B., Chu, T. T., Li, T. K. & Li, E. K. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin. Rheumatol. 26, 1495–1498 (2007).
Kiortsis, D. N. et al. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J. Rheumatol. 33, 921–923 (2006).
Soubrier, M. et al. Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis. Joint Bone Spine 75, 22–24 (2008).
Saiki, O. et al. Infliximab but not methotrexate induces extra-high levels of VLDL-triglyceride in patients with rheumatoid arthritis. J. Rheumatol. 34, 1997–2004 (2007).
Popa, C. et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 66, 1503–1507 (2007).
Popa, C. et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 64, 303–305 (2005).
Garces, S. P. et al. Anti-tumour necrosis factor agents and lipid profile: a class effect? Ann. Rheum. Dis. 67, 895–896 (2008).
Ablin, J. N. et al. Effect of anti-TNFα treatment on circulating endothelial progenitor cells (EPCs) in rheumatoid arthritis. Life Sci. 79, 2364–2369 (2006).
Jacobsson, L. T. et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J. Rheumatol. 32, 1213–1218 (2005).
Dixon, W. G. et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 56, 2905–2912 (2007).
Szabó, Z. et al. Effects of rituximab and adalimumab on vascular function in established and early rheumatoid arthritis. Hung. Rheumatol. 49, 137 (2008).
Sidiropoulos, P. I. et al. Sustained improvement of vascular endothelial function during anti-TNFα treatment in rheumatoid arthritis patients. Scand. J. Rheumatol. 38, 6–10 (2009).
Nishida, K., Okada, Y., Nawata, M., Saito, K. & Tanaka, Y. Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (IFX), an anti-TNF-alpha antibody. Endocr. J. 55, 213–216 (2008).
Spanakis, E. et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J. Rheumatol. 33, 2440–2446 (2006).
Cauza, E. et al. Intravenous anti-TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wien. Klin. Woschenschr. 114, 1004–1007 (2002).
van Eijk, I. C. et al. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. Arthritis Rheum. 60, 1324–1330 (2009).
Lewicki, M., Kotyla, P. & Kucharz, E. Etanercept increases adiponectin level in woman with rheumatoid arthritis. Clin. Rheumatol. 27, 1337–1338 (2008).
Oguz, F. M., Oguz, A. & Uzunlulu, M. The effect of infliximab treatment on insulin resistance in patients with rheumatoid arthritis. Acta Clin. Belg. 62, 218–222 (2007).
Marra, M. et al. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. Int. J. Immunopathol. Pharmacol. 20, 731–736 (2007).
van Eijk, I. C. et al. Decrease of fructosamine levels during treatment with adalimumab in patients with both diabetes and rheumatoid arthritis. Eur. J. Endocrinol. 156, 291–293 (2007).
Acknowledgements
This work was supported by research grants from the Hungarian Scientific Research Fund (Z. Szekanecz) and a Bolyai Research Grant (P. Soltész).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Szekanecz, Z., Kerekes, G. & Soltész, P. Vascular effects of biologic agents in RA and spondyloarthropathies. Nat Rev Rheumatol 5, 677–684 (2009). https://doi.org/10.1038/nrrheum.2009.219
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2009.219
This article is cited by
-
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician
Nature Reviews Rheumatology (2024)
-
Associations of vascular and bone status in arthritis patients
Scientific Reports (2021)
-
Effects of 1-year anti-TNF-α therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis
Rheumatology International (2020)
-
Common mechanisms and holistic care in atherosclerosis and osteoporosis
Arthritis Research & Therapy (2019)
-
Stiffening of aorta is more preferentially associated with rheumatoid arthritis than peripheral arteries
Rheumatology International (2019)